Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Advanced BiomedADVB +3.69%12 Cash-to-Debt is 86.77 as of Mar. 2026, which is 319% above its 10-year median of 20.69. GuruFocus rates ADVB with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 209 Medical Diagnostics & Research companies, Advanced Biomed ranks better than 93.78% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Advanced Biomed's cash to debt ratio for the quarter that ended in Mar. 2026 was 86.77.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Advanced Biomedcould pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for Advanced Biomed's Cash-to-Debt or its related term are showing as below:
ADVB'
s Cash-to-Debt Range Over the Past 10 Years
Min: 8.46 Med: 20.69 Max: 124.05
Current: 86.77
During the past 5 years, Advanced Biomed's highest Cash to Debt Ratio was 124.05. The lowest was 8.46. And the median was 20.69.
ADVB's Cash-to-Debt is ranked better than 93.78% of 209
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.13
vs ADVB: 86.77
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Advanced Biomed Cash-to-Debt Related Terms
Advanced Biomed Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Advanced Biomed's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Diagnostics & Research subindustry, Advanced Biomed's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Biomed Cash-to-Debt vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Advanced Biomed's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Advanced Biomed's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Biomed (ADVB) has a Cash-to-Debt of 86.77 as of Mar. 2026. This is 319% above median its historical median of 20.69. Over the past decade, Advanced Biomed's Cash-to-Debt has ranged from 8.46 to 124.05. According to the industry distribution chart, Advanced Biomed ranks #13 out of 209 companies in the Medical Diagnostics & Research industry, placing it in the top 6.2%.
Is Advanced Biomed's Cash-to-Debt too high?
Advanced Biomed's current Cash-to-Debt of 86.77 is 319% above median its 10-year median of 20.69. Over the past 10 years, this metric has ranged from a low of 8.46 to a high of 124.05. The Medical Diagnostics & Research industry median Cash-to-Debt is 1.13. Advanced Biomed's value of 86.77 is 7578.8% above this industry median. Based on the distribution chart, Advanced Biomed ranks #13 out of 209 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Advanced Biomed has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Advanced Biomed's Cash-to-Debt compare to BIOQ and QUCY?
According to the Medical Diagnostics & Research industry distribution chart, Advanced Biomed ranks #13 out of 209 companies for Cash-to-Debt. This places Advanced Biomed in the top 6% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 1.13. Advanced Biomed's value of 86.77 is 7578.8% above this benchmark. Historically, Advanced Biomed's own Cash-to-Debt has ranged from 8.46 to 124.05 over the past decade. While the company's 10-year median is 20.69 vs. the industry median of 1.13, Advanced Biomed has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Diagnostics & Research company?
The median Cash-to-Debt among Medical Diagnostics & Research companies is 1.13, based on 209 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Advanced Biomed's current Cash-to-Debt of 86.77 is 7578.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Cash-to-Debt is 1.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Biomed's current Cash-to-Debt is 86.77, which is 319% above median its own 10-year median of 20.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Biomed stock overvalued right now?
Advanced Biomed (ADVB) has a current Cash-to-Debt of 86.77. The current Cash-to-Debt is 86.77, which is 319% above median its 10-year median of 20.69 and 7578.8% above the Medical Diagnostics & Research industry median of 1.13. Advanced Biomed's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Advanced Biomed (ADVB), the current Cash-to-Debt is 86.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.
12GF Score
Get the complete analysis for ADVB
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADVB has been successfully added to your 
